Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

(2021) Anja Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

(2021) Merryn Voysey et al.   LANCET

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

(2021) Ulf M Geisen et al.   ANNALS OF THE RHEUMATIC DISEASES

Serological response to mRNA COVID-19 vaccines in IBD patients receiving biological therapies

(2021) Serre-Yu Wong et al.   GASTROENTEROLOGY

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

(2021) Nicholas A Kennedy et al.   GUT

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

(2021) Eric J Haas et al.   LANCET

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2

(2021) Parakkal Deepak et al.   ANNALS OF INTERNAL MEDICINE

Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series

(2021) Caoilfhionn M. Connolly et al.   ANNALS OF INTERNAL MEDICINE

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

(2021) Rebecca H Haberman et al.   ANNALS OF THE RHEUMATIC DISEASES

Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

(2021) Mark M. Painter et al.   IMMUNITY

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

(2021) Emma C Wall et al.   LANCET

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

(2021) Aziz Sheikh et al.   LANCET

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

(2021) Dami A. Collier et al.   NATURE

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

(2021) Jackson S. Turner et al.   NATURE

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

(2021) Moriah Bergwerk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom

(2021) Jia Wei et al.   Nature Microbiology

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

(2021) Satveer K Mahil et al.   Lancet Rheumatology

Effect of IBD medications on COVID-19 outcomes: results from an international registry

(2020) Ryan C Ungaro et al.   GUT

Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study

(2020) Satveer K. Mahil et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

(2020) Jeffrey Seow et al.   Nature Microbiology